Correspondence 0001193125-23-233460 from Neumora Therapeutics, Inc. (NMRA) (CIK 0001885522) (NMRA)
Neumora Therapeutics, Inc. (NMRA) (CIK 0001885522)
Date: Sept. 12, 2023 · CIK: 0001885522 · Accession: 0001193125-23-233460
AI Filing Summary & Sentiment
File numbers found in text: 333-274229
Letter
Neumora Therapeutics, Inc.
490 Arsenal Way, Suite 200
Watertown, Massachusetts 02472
September 12, 2023
VIA EDGAR AND E-MAIL
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549-6010
Attention:
Eric Atallah
Al Pavot
Daniel Crawford
Laura Crotty
Re:
Neumora Therapeutics, Inc. Registration Statement on Form S-1 (Registration No. 333- 274229)
Ladies and Gentlemen:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (Registration No. 333-274229) (the “Registration Statement”) of Neumora Therapeutics, Inc. (the “Company”). We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on September 14, 2023, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Phillip Stoup at (415) 395-8216 or B. Shayne Kennedy at (714) 755-8181.
Thank you for your assistance in this matter.
Very truly yours,
NEUMORA THERAPEUTICS, INC.
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
Neumora Therapeutics, Inc.
490 Arsenal Way, Suite 200
Watertown, Massachusetts 02472
September 12, 2023
VIA EDGAR AND E-MAIL
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549-6010
Attention:
Eric Atallah
Al Pavot
Daniel Crawford
Laura Crotty
Re:
Neumora Therapeutics, Inc. Registration Statement on Form S-1 (Registration No. 333- 274229)
Ladies and Gentlemen:
In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby
request acceleration of the effective date of the Registration Statement on Form S-1 (Registration No. 333-274229) (the “Registration
Statement”) of Neumora Therapeutics, Inc. (the “Company”). We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on September 14, 2023, or as soon
as practicable thereafter. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Phillip Stoup at (415)
395-8216 or B. Shayne Kennedy at (714) 755-8181.
Thank
you for your assistance in this matter.
Very truly yours,
NEUMORA THERAPEUTICS, INC.
By:
/s/ Henry O. Gosebruch
Henry O. Gosebruch
President and Chief Executive Officer
cc:
Paul L. Berns, Neumora Therapeutics, Inc.
Phillip Stoup, Latham & Watkins LLP
B. Shayne Kennedy, Latham & Watkins LLP
Charles S. Kim, Cooley LLP
Kristin VanderPas, Cooley LLP
Dave Peinsipp, Cooley LLP
Denny Won, Cooley LLP